The UK group will collect and analyse positron emission tomography images generated by the Global Alzheimer's Platform Foundation’s (GAP) Bio-Hermes study.
Its main purpose is the development of a database to investigate biomarkers on a head-to-head basis in conjunction with medical history elements.
The trial will include 1,000 volunteers over the age of 60 screened for pre-clinical Alzheimer's as well as prodromal and mild dementia forms of the disease.
Earlier assessments of the condition consistently suggest a build-up of beta-amyloid and tau proteins as well neurofibrillary tangles are “sentinel events” in Alzheimer's.
IXICO said the contract will “contribute to the company's already strong year-end order book”.
In a statement, IXICO's chief executive Giulio Cerroni noted: "With a reinvigorated level of interest in Alzheimer's Disease, we are excited about the prospects of a long-term collaboration with our colleagues at GAP who share our own commitment to reducing the time, cost, and risk for Alzheimer's Disease trials.
“The support provided by IXICO staff on Bio-Hermes is an important commercial development in enhancing IXICO's market position in neuroimaging for Alzheimer's Disease clinical trials."